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Key questions
What is already known about this subject?
 ► Some in-vivo studies have debated the role of pac-
ing to mitigate aortic regurgitation and its use as 
therapy to this aim.
 ► The discrepancies on the results are mainly due to 
some inaccuracies of in-vivo measurements and the 
improper use of aortic regurgitation index to assess 
the enhancement of the grade of insufficiency.
What does this study add?
 ► The study indicates that pacing is ineffective as a 
treatment for postoperative aortic regurgitation, and 
may result detrimental both in term of regurgitation 
and heart power demand.
How might this impact on clinical practice?
 ► The findings suggest a more widespread use of 
the left ventricular power as a heart performance 
parameter that allows an effective and consis-
tent comparison between different heart beating 
conditions.
AbstrAct
Background and objective Clinical evaluation of 
pacing therapy in mitigating the aortic insufficiency 
after transchateter aortic valve implantation often gives 
contradictory outcomes. This study presents an in vitro 
investigation aimed at clarifying the effect of pacing on 
paravalvular leakage.
Methods A series of in vitro tests reproducing the heart 
operating changes clinically obtained by pacing was 
carried out in a 26 mm Edwards Sapien XT prosthesis 
with mild paravalvular leakage. The effect of pacing on 
the regurgitant volumes per cycle and per minute was 
quantified, and the energy and power consumed by the 
left ventricle were calculated.
Results Results indicate that though pacing results 
in some reduction in the total regurgitation per cycle, 
the volume of fluid regurgitating per minute increases 
substantially, causing overload of left ventricle.
Conclusions Our tests indicate no effective 
haemodynamic benefit from pacing, suggesting a 
prudential clinical use of this therapy for the treatment of 
postoperative aortic regurgitation.
IntRoduCtIon
Significant postoperative aortic regurgita-
tion due to paravalvular leakage (PVL) is a 
common complication after transcatheter 
aortic valve implantation (TAVI), with inci-
dence ranging from 5% to 25%, associated 
with an increase in early and late postopera-
tive mortality.1–4
Pacing has been adopted as temporary 
or permanent therapy to mitigate PVL in 
patients affected by moderate/severe regur-
gitation after TAVI.5 This approach is based 
on the concept that a shorter diastolic phase 
reduces the time available for blood to flow 
back into the ventricle, thus diminishing the 
ventricular overload.6 7 However, the clinical 
outcomes described in the literature are often 
contradictory.7–11 These inconsistencies can 
be attributed to the relatively reduced accu-
racy of in vivo measurements approaches,12 as 
well as the difficulty in comparing different 
courts of patients examined at various centres.
The present study aims at assessing in vitro 
the effect of pacing on the cardiac load and 
its impact on the power consumption of 
the heart. In order to allow direct compar-
ison between the different operating condi-
tions, an in vitro approach was adopted. This 
enables full control of the working parame-
ters, as well as an accurate measurement of 
the functional quantities. Tests mimicking 
mild PVL after TAVI and different pacing 
were carried out, and the efficacy of pacing 
was verified by investigating its effect on 
the ventricular overload per beat and per 
unit time (ie, per minute). The distinction 
between these two time references becomes 
fundamental when adopting pacing, as quan-
tities typically measured over a single heart 
cycle do not necessarily reflect the global 
benefit and may lead to erroneous interpre-
tations of the results.
MetHods
A 26 mm diameter Edwards SAPIEN XT was 
used as testing valve. This was released into 
a silicon cylindrical holder of 23 mm diam-
eter by standard implantation procedure. 
The holder included a crescent shape axial 
grove (5 mm of minor axis, 3 mm of major 
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Figure 1 Sketch of the housing valve apparatus as reported 
by Burriesci et al.13
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semiaxis and total area Aorifice 12 mm
2) (figure 1) causing 
mild PVL.13
Following well-developed methodologies for evaluation 
of cardiovascular devices and in vitro haemodynamics 
features,14 15 physiological pulsatile flow conditions were 
replicated in a hydromechanical pulse duplicator (ViVitro 
System, ViVitro Labs Inc, Victoria, Canada). The equip-
ment includes a hydraulic circuit mimicking the human 
systemic circulation, comprising an atrial, a ventricular 
and an aortic chamber. The pulsatile flow is produced 
by a computer-driven piston pump, and localised dissipa-
tion and compliance chambers are placed downstream of 
the aortic root to account for the Windkessel effect. Flow 
through the ventricular and aortic chambers is measured 
with an electromagnetic flowmeter (model 501, Caro-
lina Medical Electronics, Inc, King, North Carolina, 
USA), and pressure in the three chambers is recorded 
from three 8-French Millar microtip transducers (Millar 
Instruments, Houston, Texas, USA). Phosphate buffered 
saline solution at 37°C was adopted as testing fluid.
Six tests were carried out at different hydrodynamic 
working conditions, as reported in table 1. Heart rate 
(HR) was varied in the range 60–110 bpm. The cardiac 
output (CO) and mean aortic pressure (pAo) were set 
to replicate conditions observed in vivo,16 17 but conve-
niently scaled to match the optimum operating range 
of the pulse duplicator. In particular, CO was increased 
about proportionally with HR in the range 3.4–6.2 L/
min (ie, a range twice smaller than the one measured 
in vivo14), while pAo was maintained constant at 100 mm 
Hg. To better represent the changes in physiological 
contraction of the left ventricle with the increase of HR, 
the systolic percentage of the cycle was also extended, in 
agreement with the clinical evidence.18
For each testing condition, the instantaneous pressures 
in the aortic and ventricular chambers and the flow rate 
thorough the valve were measured during the entire 
cycle, collecting 256 samples per cycle.
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Figure 2 The averaged flow measured over the 10 cardiac cycles as function of the time. Flow was measured at HR=60 bpm 
(solid black line), HR=70 bpm (dashed black line), HR=80 bpm (dotted black line), HR=90 bpm (solid grey line), HR=100 bpm 
(dashed grey line) and HR=110 bpm (dotted grey line). CV, closing volume; HR, heart rate; LV, leakage volume; RV, regurgitant 
volume; SV, stroke volume.
Data were averaged over 10 consecutive cycles and used 
to extract the following quantities:
 ► Stroke volume (SV (mL)).
 ► Closing regurgitant volume (CV (mL)), corre-
sponding to the backflow as the valve leaflets move 
from the open to the closed configuration.
 ► Leakage volume (LV (mL)), corresponding to back-
flow occurring when the valve is fully closed.
 ► Total regurgitant volume (RV (mL)), equal to the 
sum of CV and LV.
 ► Regurgitant fraction (RF (%)), given by the ratio 
between RV and SV.
 ► Closing regurgitant mean flow rate (CFR (mL/min)), 
given by the product of CV and HR.
 ► Leakage mean flow rate (LFR (mL/min)), given by 
the product of LV and HR.
 ► Total regurgitant mean flow rate (RFR (mL/min)), 
given by the product of RV and HR.
 ► Energy per cycle (E (J)), calculated as ventricular 
pressure–volume integral (ie, ventricular pressure–
volume loop area).
 ► Power (P (W)), calculated as the ratio between the 
energy E and the heart beat duration:
 P = E · HR/60 (1).
Results
The values determined for the above parameters at the 
different testing conditions are summarised in table 1.
The transaortic flow wave behaviour for the six study 
cases is depicted in figure 2. Peak flow ranges from 
510 mL/s at HR=60 bpm to 610 mL/s at HR=110 bpm. 
Leakage volumetric flow rate (ie, closed valve condition) 
is similar for all conditions and ranges between 15 and 20 
mL/s. On the contrary, regurgitant volumetric flow rate 
at peak increases from 90 mL/s at HR=60 bpm to 215 
mL/s at HR=100 bpm.
Figure 3 shows the main measured parameters, for 
example, backflow per cycle, mean backflow per minute, 
RF, energy loss and power per cycle, as described below.
The RV measured at the different testing configura-
tions, with the contributions from both CV and LV, is 
summarised in the panel a of figure 3. As HR is raised 
from 60 bpm to 110 bpm, the closing volume increases 
from 5.3 mL to 8.2 mL; conversely, LV reduces from 9.3 
mL to 5.1 mL. The RV keeps between 12.9 mL and 14.6 
mL for all testing conditions. Similarly, the RF keeps 
about constant with HR, ranging from 20.4% (HR=60 
bpm) to 18.8% (HR ≥90 bpm) (see figure 3A).
The RFR (ie, the total RV per minute) and the two 
contributions due to CFR and LFR are reported in panel 
B of figure 3. By raising HR from 60 bpm to 110 bpm, 
both regurgitant and closing mean flow rates increase 
monotonically from 875 mL/min to 1475 mL/min and 
from 320 mL/min to 900 mL/min, respectively, while 
leakage mean flow rate varies little, staying in the range 
between 510 mL/min and 623 mL/min.
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Figure 3 Measured parameter on aortic left ventricle 
performance as function of HR. (A) RV (white circle), 
the closing volume CV (triangle), the LV at closed valve 
LV (diamond) and along the second axis the RF (grey 
circle). Bars error are omitted for clarity. (B) Estimated 
total regurgitant mean flow rate (RFR) (circle) and the two 
contributions due to closing mean flow rate (CFR) (triangle) 
and leakage mean flow rate (LFR) (diamond) (bars error are 
negligible). (C) estimated power P (white circle) and energy 
per stroke E (grey circle) of the left ventricle (bars error are 
negligible). Data are averaged over the 10 cycles. CV, closing 
volume; HR, heart rate; LV, leakage volume; RF, regurgitant 
fraction; RV, regurgitant volume.
Left ventricle energy per stroke E and power P as a 
function of HR are shown in the panel c of figure 3. E 
varies slightly between 1.3 and 1.4 J, while the associated 
power P doubles from 1.3 to 2.6 W.
dIsCussIon
Various studies performed in the 1960s with the dye dilu-
tion technique observed a reduction of RV in patients 
with increased8 HR and in patients with severe RF.9 
Conversely, similar measurements with electromagnetic 
velocimetry performed by Brawley and Morrow10 in the 
same period did not produce consistent changes in RV 
with higher HR. This was confirmed by Judge et al11 who, 
in the early 1970 s, reported that though the increase 
of HR induces a rise in CO and a reduction of SV and 
RF, it has no significant effect on the RV per minute. In 
a later study from Firth et al,7 the survey of 12 patients 
indicated that though increased HRs were associated 
with large reductions in RV per stroke, only minor reduc-
tions of RF could be observed and no substantial modi-
fication in the RV per minute. Again, these conclusions 
are disputed by a recent study by Ali et al5 that reports 
clinical benefits in patients affected by aortic regurgita-
tion after treatment with permanent pacing. The efficacy 
of the therapy is assessed by an overall enhancement of 
the aortic regurgitation index (ARI), that is, the ratio of 
the difference between the diastolic blood pressure and 
the left ventricular end-diastolic pressure (LVEDP) to the 
systolic blood pressure (ARI=(DBP−LVEDP)/SB).19
Some of the discrepancies in these studies may be 
justified by the use of different in vivo measurement 
techniques, as well as the limited accuracy of clinically 
available anemometric methodologies. This limitation is 
acknowledged in a topical work by Pibarot et al, which 
demonstrates the relatively low resolution of in vivo 
measurements through transoesophageal echo (the best 
cost–benefit ratio methodology for in vivo flow measure-
ments) in quantifying the RV, and questions the reliability 
of ARI, especially when it is used to grade regurgitation as 
a function of HR.12
In the present study, for the first time, in vitro tests 
are carried out in order to verify and quantify the effect 
of pacing in presence of mild aortic regurgitation after 
TAVI. Flow measurement shows that the leakage rate 
determined in the diastolic period after full valve closure 
(LV per unit time) does not vary substantially for the 
tested conditions (between 15 mL/s and 20 mL/s), and 
it is consistent in value with the leakage rate expected 
from fluid dynamics theory (for more detail, see online 
supplementary appendix A). This is not surprising, 
because the instantaneous diastolic regurgitant flow 
rate is strictly dependent on the mean diastolic pressure 
difference (ΔpD) (ie, the differential pressure acting 
across the valve in diastole) that, due to the choice of 
setting a fixed value for the mean aortic pressure (100 
mm Hg), is similar for all testing cases. This implies that, 
as the diastolic period reduces with pacing, LV over a 
single cardiac cycle decreases about proportionally, as 
reflected in the diagram in figure 3A. On the contrary, 
the variation of CV and LV are counterbalanced, so 
that the total RV experiences only a small reduction of 
about 10% with increased HR. The increment of closing 
volume with HR observed in vitro is determinant to 
maintain the RV constant. No reference was found in 
the clinical literature to support or confute the rise in 
closing volume with pacing; however, even assuming a 
constant value of closing volume for all tests (eg, CV=5 
mL) the reduction of RF would be at most 5% and hence 
insufficient to mitigate effectively the valve insufficiency. 
Similarly to RV, also the effect of pacing on the RF is 
reduced, as shown in figure 3A.
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A comprehensive analysis of the phenomenon has to 
take into account the variation in the number of cycles 
per minute resulting from pacing. Conversion of the 
regurgitant parameters into mean flow rates modifies 
the diagram in figure 3A as shown in figure 3B. Trivi-
ally, the global volume of blood returning back from the 
aorta into the ventricle per each minute is given by the 
RV occurring at each cycle, multiplied by the number of 
cycles in 1 min. Hence, all quantities defining the back-
flow increase proportionally with HR. It is interesting 
observing that the conversion from LV (defined per 
cycle) to leakage mean flow rate (defined per minute) 
results into a stabilisation of the latter, which becomes 
approximately constant. This is justified by the fact that 
the instantaneous diastolic regurgitant flow rate is about 
constant, as previously discussed, and the total diastolic 
period decreases only slightly with HR rising from 60 
to 110 (in a minute, the cumulative time of all diastoles 
varies from about 41 s at 60 bpm to about 34 s at 110 
bpm).
The most critical finding of the study is that the overall 
effect of pacing is a significant increment of the regurgi-
tant mean flow rate, necessarily associated with a higher 
overload for the heart.
Such result is well reflected in the behaviour of the 
energy consumed by the left ventricle during the single 
cycle, E, and of the power, P, corresponding to the energy 
consumption per minute. E is almost constant for all HRs, 
but the overall work expended per minute increases, 
as shown in the diagram of the required ventricular 
power P, which doubles within the tested HR range (see 
figure 3C).
The present analysis is limited to the case of mild 
prosthetic aortic valve regurgitation, a condition that 
is common in patients after transcatheter aortic valve 
replacement (TAVR), as well as the need for post implan-
tation pacing to overcome the development of complete 
AV block as recently reported in multicentre studies, in 
which the permanent pacemaker was implanted up to 
17.4% of the patients.20 21 However, the outcomes can 
be confidently extended also in presence of a moderate 
regurgitation, as well as a severe grade of PVL, although, 
in the latter, reoperation is still the only indicated ther-
apeutic option, thus limiting the number of patient 
requiring pacing.
Of course, the presented study is based on a number 
of necessary assumptions that may affect the relevance 
of the results, such as the adoption of idealised anatom-
ical and operating conditions. In particular, the use of 
a rigid aortic root and a straight paravalvular orifice 
of constant semielliptical cross section is a generalisa-
tion, which suggests some caution when transposing 
the presented results to the clinical case. Also, the fluid 
behaviour is necessarily dependent on the dynamic 
of the selected valve, and on the features imposed to 
describe the contraction phase (in the present in 
vitro case, the imposed contraction of the ventricular 
chamber).
The increment in mean aortic pressure typically 
observed with increased HR17 is expected to result 
into larger RVs than the volumes measured here, with 
constant pAo.
Another approximation consists in the use of saline 
solution, which might result into different velocity 
profiles inside the paravalvular orifice, due to the 
reduced viscosity (this is about one fourth as the viscosity 
of blood at 37°C). However, theoretical considerations 
indicate that, for the used working conditions, the effect 
of viscosity is expected to be negligible.22
ConClusIons
This study presents, for the first time, a systematic study 
of the efficacy of pacing as a treatment for PVL. The left 
ventricular operating conditions under pacing were simu-
lated in vitro on a Sapien XT of size 26 mm, imposing 
mild paravalvular leakage.
The RVs per cycle and per minute, the energy and 
power consumed by the ventricle in a single beat were 
estimated at different HRs.
Although the shorter diastolic phase for high HRs causes 
a slight reduction of RF measured over the cardiac cycle, 
the volume of fluid regurgitating per minute increases 
substantially, causing overload of the left ventricle.
The presented results indicate that pacing produces 
no effective haemodynamic benefits in patients with AR, 
in terms of regurgitation, and can result in significant 
increases in heart power demand. Moreover, collateral 
complications may arise due a persistent non-physiolog-
ical shear stress, whose quantification has been demon-
strated being rather complex.23 This suggests a prudential 
use of temporary or permanent therapy for the treatment 
of postoperative aortic regurgitation.
The study demonstrate that parameters typically 
adopted to evaluate and quantify aortic insufficiency 
(eg, RV and RF), based on a single cardiac cycle, are 
not adequate to capture the effect of HR on the cardiac 
performance. This may result in erroneous interpreta-
tion and quantification of the clinical benefit deriving 
from pacing, leading to its improper adoption.
To correctly evaluate the efficacy of this therapy, alter-
native parameters based on a fixed chronological period 
including several heart beats (eg, 1 min) should be used. 
In particular, we recommend the use of the left ventric-
ular power as a heart performance parameter, as it allows 
an effective and consistent comparison between oper-
ating conditions characterised by different heart rhythms. 
In addition, other methodologies might be explored by 
considering coexisting features related to altered aortic 
valve haemodynamics, such as the sound of regurgitant 
jet.24–26
Finally, further specific studies would be appropriate 
to frame the role of the energy and power consump-
tion in the perspective of optimisation of heart perfor-
mance. This aspect may potentially enhance also the 
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comprehension of the cardiac physiopathology charac-
terised by ventricular remodelling.
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